--- title: "Pre-market hot trades in US stocks: Lakeland Industries up 15.36% pre-market; Lifezone Metals up 13.71% pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/283317598.md" description: "Lakeland Industries pre-market rose 15.36%; Lifezone Metals pre-market rose 13.71%; Psyence Biomedical pre-market rose 103.03%; Clearmind Medicine pre-market rose 93.08%; Theriva Biologics pre-market rose 63.30%" datetime: "2026-04-20T08:28:13.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283317598.md) - [en](https://longbridge.com/en/news/283317598.md) - [zh-HK](https://longbridge.com/zh-HK/news/283317598.md) --- # Pre-market hot trades in US stocks: Lakeland Industries up 15.36% pre-market; Lifezone Metals up 13.71% pre-market **Popular Pre-Market Trades in US Stocks** Lakeland Industries pre-market rose 15.36%. Based on recent key news: 1. On April 17, Lakeland Industries announced its FY2026 financial report, with a revenue growth of 15.2%, but profit margins were compressed due to cost pressures. The company simplified its business portfolio through strategic acquisitions and divestitures, and expects to achieve high single-digit revenue growth and positive cash flow in FY2027. This news drove the stock price up. Source: SEC announcement 2. On April 17, Lakeland Industries completed NFPA 1970 certification, which is expected to improve product supply and showcase at FDIC 2026. The new leadership and streamlined business portfolio enhanced capital strength, aiming for more consistent profit margins and inventory efficiency. This move boosted market confidence. Source: Company announcement 3. On April 17, Lakeland Industries showcased its integrated fire and safety brands at the largest global fire industry event, which is expected to bring over $5 million in incremental business opportunities. This further solidified the company's market position in Europe and the Asia-Pacific region. Source: Company announcement. The fire industry event boosted market confidence, with significant capital inflow. Lifezone Metals pre-market rose 13.71%, with no significant news recently. Trading is active, with clear capital flow. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. **Top Gainers in US Pre-Market Stocks** Psyence Biomedical pre-market rose 103.03%. Based on recent key news: 1. On April 17, Psyence Biomedical announced its pharmaceutical-grade psilocybin product NPX-5 for clinical trials. The company's CEO stated that this move will accelerate the expansion of clinical infrastructure, supporting continuous medication for patients. This news drove the stock price up 69.85% in pre-market. Source: GlobeNewswire 2. On April 18, US President Trump signed an executive order to accelerate the research and approval process for psychedelic drugs, particularly for substances like ibogaine. This favorable policy news drove the stock prices of related companies up. Source: Reuters 3. On April 17, Psyence Biomedical's API development department obtained federal licensing to support global distribution and clinical projects. This move enhanced market confidence in the company's future development, driving the stock price up. Source: Nasdaq. The accelerated research policy for psychedelic drugs has increased market attention. Clearmind Medicine pre-market rose 93.08%. Based on recent key news: 1. On April 19, US President Trump signed an executive order to accelerate the research and approval process for psychedelic therapies. This aims to help veterans suffering from severe mental illnesses by providing new treatment options. Clearmind Medicine's stock price surged significantly due to its important position in the psychedelic drug field. The research policy for psychedelic drugs is favorable Theriva Biologics pre-market rose 63.30%. Based on recent key news: 2. On April 17, Theriva Biologics announced that it will present additional data from its VIRAGE Phase 2B clinical trial at the AACR 2026 Annual Meeting. This trial involves the application of VCN-01 in metastatic pancreatic cancer, demonstrating its potential in improving overall survival and progression-free survival. This news drove the stock price up. 3. On April 17, the company plans to conduct a low-dose study to test whether more frequent and extended administration of VCN-01 can further improve outcomes. This move shows the company's confidence in its product, further boosting market sentiment. 4. On April 17, posters released by Theriva Biologics showed that when VCN-01 is used in combination with gemcitabine/albumin-bound paclitaxel, both overall survival and progression-free survival of patients improved. This data enhanced investor confidence in the company's products, driving the stock price up. The biotechnology industry has been active recently, with investors focusing on the progress of new therapies ### Related Stocks - [LAKE.US](https://longbridge.com/en/quote/LAKE.US.md) - [LZM.US](https://longbridge.com/en/quote/LZM.US.md) ## Related News & Research - [How Trump’s trade push against Canada backfired](https://longbridge.com/en/news/286675578.md) - [U.S. VICE PRESIDENT VANCE: BUT THAT'S NOT WHAT TRUMP OR IRAN WANTS](https://longbridge.com/en/news/286975771.md) - [TRUMP ON IRAN: THEY WON'T ACQUIRE A NUCLEAR WEAPON; WE WILL RESOLVE THE CONFLICT RAPIDLY](https://longbridge.com/en/news/286978249.md) - [Trump's psychedelic drug order boosts investor interest with promise of faster reviews](https://longbridge.com/en/news/286750347.md) - [DC Circuit eyes off-ramp in Trump’s national security feud with Anthropic](https://longbridge.com/en/news/286952821.md)